Company: DAWN
Filing Date: 2025-11-24
Form Type: 8-K
Source: 0001193125-25-292096
Chunk: 0

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-24
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On November 24, 2025, Day One Biopharmaceuticals, Inc. (the “ Company”) issued a press release announcing three-year results from the Company’s OJEMDA™(tovorafenib) pivotal Phase 2 FIREFLY-1trial.

Additionally, on November 24, 2025, the Company updated its corporate presentation to reflect the updated data from the FIREFLY-1trial.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form8-K. A copy of the updated corporate presentation is attached as Exhibit 99.2 to this Current Report on Form8-K.

The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.